Physician

Rafael Valencia, M.D.

According to 2025 Medicare claims, Rafael Valencia, M.D. (NPI: 1366494247) practices interventional cardiology in the Las Vegas-Henderson-North Las Vegas, NV market, with the plurality of this provider's patient population coming from Clark, NV. This provider's primary affiliated billing organization is NEVADA HEART AND VASCULAR CENTER RESH LLP (NPI: 1659387934; TIN: 200562668) and primary practice location at 89118-3035. Valencia is affiliated with the Silver State ACO LLC (ACO ID: A2251), participating under the MSSP model.

Valencia's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 2,497 traditional Medicare patients, billed 28,842 HCPCS/CPT codes, and received $2,440,172 in Medicare payments. The top billing code was A9555 (Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries). Part D data shows 5,079 prescription claims across 753 beneficiaries totaling $1,306,915 in drug costs, led by Xarelto (Rivaroxaban). 2020 DME data shows 23 claims. Open Payments data shows 109 records totaling $1,976. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $1,064,442 to $2,440,172. Similarly, Part D prescription costs have moved sharply higher in recent years, from $152,283 to $1,306,915. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,673	24,942	$1,064,442
2016	2,453	36,351	$1,245,071
2017	1,939	31,094	$1,183,131
2018	1,677	26,050	$1,221,963
2019	1,571	27,312	$1,157,971
2020	1,223	25,885	$1,483,786
2021	1,251	22,735	$1,315,139
2022	1,224	21,082	$1,289,989
2023	2,011	24,973	$2,290,289
2024	2,497	28,842	$2,440,172

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	283	1,987	$152,283
2016	331	2,223	$251,356
2017	376	2,554	$299,719
2018	454	3,133	$402,947
2019	510	3,425	$460,265
2020	591	4,040	$656,593
2021	674	4,508	$895,919
2022	691	4,695	$1,115,485
2023	702	4,875	$1,315,332
2024	753	5,079	$1,306,915

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	18	$414
2019	N/R	103	$3,012
2020	N/R	23	$191
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
A9555	Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries	875	1,753	$401
78434	Nuclear medicine study of heart muscle blood flow by pet	608	609	$104
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	486	703	$86
93015	Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician	1,035	1,037	$53
J2785	Injection, regadenoson, 0.1 mg	936	3,752	$5

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xarelto	Rivaroxaban	352	27,030	$491,244
Eliquis	Apixaban	164	11,150	$215,400
Entresto	Sacubitril/Valsartan	109	6,162	$132,071
Jardiance	Empagliflozin	65	5,130	$99,167
Repatha Sureclick	Evolocumab	69	4,750	$92,347

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	109	$1,976	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Rafael Valencia, M.D.?

Tedicare shows public-source Medicare data for Rafael Valencia, M.D. (NPI 1366494247), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Rafael Valencia, M.D. have ACO affiliation data?

Rafael Valencia, M.D. is shown with ACO affiliation data for Silver State ACO LLC (MSSP, ACO ID A2251).

What billing organization is linked to Rafael Valencia, M.D.?

Rafael Valencia, M.D. is linked to NEVADA HEART AND VASCULAR CENTER RESH LLP (billing NPI 1659387934) in the available physician profile data.

Does Rafael Valencia, M.D. have Open Payments data?

Rafael Valencia, M.D. has 109 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.